Physician profile

Hillary B Loper

Endocrinology, Diabetes & Metabolism · Reisterstown, MD

NPI 1568698660

$5,439.84

in general payments reported to CMS, 2019-2025

39 companies · $751 in 2025

The $751 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,488.75

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $1,311.86 2019-2025 Ozempic, Rybelsus, Wegovy
Astrazeneca Pharmaceuticals LP $554.88 2019-2023 Farxiga
Lilly USA, LLC $356.58 2019-2025 Mounjaro, Zepbound, Trulicity
Amgen INC. $292.03 2019-2025 Prolia, Evenity, Prolia
Sanofi-Aventis U.S. LLC $267.53 2019-2025
Abbvie INC. $253.35 2021-2025
Abbott Laboratories $251.34 2020-2024 Freestyle Libre 3
Corcept Therapeutics $233.20 2021-2025 Korlym
Radius Health, INC. $191.99 2019-2025 Tymlos
Amarin Pharma, INC. $186.77 2019-2021
Xeris Pharmaceuticals, INC. $182.98 2020-2025 Gvoke Hypopen
Glaxosmithkline, LLC. $123.87 2024 Arexvy
Boehringer Ingelheim Pharmaceuticals, INC. $119.01 2019-2024 Jardiance, Synjardy, Tradjenta
Medtronic, INC. $109.68 2021-2025 Minimed 780g
Inspire Medical Systems, INC. $101.40 2025 Inspire
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $88.72 2019-2024 Capvaxive
Beta Bionics, INC. $83.91 2023-2025 Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach
Dexcom, INC. $69.22 2023-2024 Dexcom G6 Transmitter
Lifescan, INC. $67.79 2020-2022
Tandem Diabetes Care, INC. $62.84 2022-2023 T:Slim X2 Insulin Pump With Control-Iq
Janssen Pharmaceuticals, INC $61.65 2019-2020
Daiichi Sankyo INC. $53.23 2019-2020
Bayer Healthcare Pharmaceuticals INC. $50.88 2021-2025
Novartis Pharmaceuticals Corporation $34.81 2023
Insulet Corporation $34.21 2022-2023 Omnipod
Sequel Med Tech, LLC $33.28 2025 Twiist
Kyowa Kirin, INC. $29.56 2024 Crysvita
Mannkind Corporation $29.45 2021-2022
Sumitomo Pharma America, INC. $28.95 2024 Gemtesa
Becton, Dickinson and Company $26.65 2019
Grt US Holding, INC. $24.49 2022
Alnylam Pharmaceuticals INC. $20.27 2019
Takeda Pharmaceuticals U.S.A., INC. $16.79 2021
Nevro Corp. $16.20 2024 Senza
Biohaven Pharmaceutical Holding Company LTD. $15.75 2022
Regeneron Healthcare Solutions, INC. $14.90 2024 Evkeeza
Teva Pharmaceuticals USA, INC. $13.84 2022
Embecta Corp. $13.28 2023 Bd Nano 2nd Gen Pen Needle
Medtronic Minimed, INC. $12.70 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Hillary B Loper

$5,439.84

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC
Context
The $751 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

https://glasscript.com/doctor/863204/hillary-b-loper

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.